Home » Topics » Disease categories and therapies » Immune

Immune
RSS

VX-497: in vitro and in vivo findings on a selective, orally active IMPDH inhibitor

June 13, 2000

Health Canada grants priority review to Prevnar

June 13, 2000

ICN-10776 reported at Immunology 2000 to induce Th2 cytokine bias

June 9, 2000

Roche scientists disclose new series of protein kinase inhibitors and their use

June 8, 2000

Selective EP2-binding agents and their therapeutic use claimed by Ono

June 8, 2000

Vical's cationic lipid formulation selectively enhances antibody immune response to antigen pDNA

June 7, 2000

Intellivax and Active Biotech form partnership to develop streptococcal vaccine

June 7, 2000

Efforts to develop malaria vaccines reviewed at ECCMID; new candidate from SB highlighted

June 2, 2000

Repligen acquires U.S. patent rights to CTLA4-Ig

June 2, 2000

Neisseria outer membrane proteins useful for the therapy, diagnosis of infections

June 1, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...